421 related articles for article (PubMed ID: 25168947)
1. Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.
Dickneite G
Clin Lab Med; 2014 Sep; 34(3):623-35. PubMed ID: 25168947
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding.
Quinlan DJ; Eikelboom JW; Weitz JI
Circulation; 2013 Sep; 128(11):1179-81. PubMed ID: 23935012
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
4. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Pabinger I; Brenner B; Kalina U; Knaub S; Nagy A; Ostermann H;
J Thromb Haemost; 2008 Apr; 6(4):622-31. PubMed ID: 18208533
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
Schwebach AA; Waybright RA; Johnson TJ
Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
[TBL] [Abstract][Full Text] [Related]
7. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.
Pabinger-Fasching I
Thromb Res; 2008; 122 Suppl 2():S19-22. PubMed ID: 18549908
[TBL] [Abstract][Full Text] [Related]
8. ACP Journal Club. 4F-PCC was noninferior to plasma in patients with acute major bleeding who needed urgent VKA reversal.
Lang E
Ann Intern Med; 2014 Apr; 160(8):JC6. PubMed ID: 24733223
[No Abstract] [Full Text] [Related]
9. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
[TBL] [Abstract][Full Text] [Related]
10. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
11. Use of prothrombin complex concentrates in anticoagulation.
van Veen SQ; Strengers PF
Am J Hematol; 2008 Apr; 83(4):344-5. PubMed ID: 18213649
[No Abstract] [Full Text] [Related]
12. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
[TBL] [Abstract][Full Text] [Related]
13. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
Dickneite G; Hoffman M
Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
[TBL] [Abstract][Full Text] [Related]
14. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal.
Dzik WH
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S187-94. PubMed ID: 26149022
[TBL] [Abstract][Full Text] [Related]
15. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital.
Bruce D; Nokes TJ
Crit Care; 2008; 12(4):R105. PubMed ID: 18706082
[TBL] [Abstract][Full Text] [Related]
16. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
17. Beriplex--the new generation haemorrhage stopper.
Nandanan S; Goel R
J Obstet Gynaecol; 2010; 30(8):872-3. PubMed ID: 21126138
[No Abstract] [Full Text] [Related]
18. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study.
Hanke AA; Joch C; Görlinger K
Br J Anaesth; 2013 May; 110(5):764-72. PubMed ID: 23335567
[TBL] [Abstract][Full Text] [Related]
19. Prothrombin complex concentrate (Beriplex P/N).
Scott LJ
Drugs; 2009 Oct; 69(14):1977-84. PubMed ID: 19747012
[TBL] [Abstract][Full Text] [Related]
20. Use of four-factor prothrombin complex concentrate in the emergency department: a review.
Willis CM; Hall AB
J Emerg Nurs; 2015 Jan; 41(1):9-12. PubMed ID: 25016517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
